EMA Laments Lack Of Brexit Contingency Reserves
Executive Summary
Brexit is likely to be costly for the European Medicines Agency. Its management board is unhappy the agency was not allowed to use funds from its original 2016 budget to create a “contingency reserve” for dealing with the challenges relating to the departure of the UK from the EU.
You may also be interested in...
EU Postpones Decision On EMA’s New Home To November
The decision on where the European Medicines Agency should be located after the UK leaves the EU has been postponed to November. The European Council has published details of the bidding process countries must follow if they want to host the EMA.
EMA And Brexit: Rental Liabilities Could Add €350m To Relocation Costs
The EMA could be landed with a hefty rental bill on top of the actual costs of relocating to another European city, raising questions as to who will bear the financial burden. Meanwhile, the EMA has met with EU regulators to discuss future allocation of work, and Barcelona, Spain’s second city, has officially joined the race to host the agency.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.